Candel Therapeutics Statistics
Want to see CADL full AI Analyst Report?
Candel Therapeutics (CADL) Stock Statistics & Valuation Metrics
Total Valuation
Candel Therapeutics has a market cap or net worth of $715.45M. The enterprise value is $611.50M.
- Market Cap
- $715.45M
- Enterprise Value
- $611.50M
Share Statistics
Candel Therapeutics has 76,518,560 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 76,518,560
- Owned by Insiders
- 8.86%
- Owned by Institutions
- 32.04%
Financial Efficiency
Candel Therapeutics’s return on equity (ROE) is -0.74 and return on invested capital (ROIC) is -41.38%.
- Return on Equity (ROE)
- -0.74
- Return on Assets (ROA)
- -0.30
- Return on Invested Capital (ROIC)
- -41.38%
- Return on Capital Employed (ROCE)
- -0.42
- Revenue Per Employee
- 0
- Profits Per Employee
- -694.22K
- Employee Count
- 55
- Asset Turnover
- 0.00
- Inventory Turnover
- 0.00
Valuation Ratios
The current PE Ratio of Candel Therapeutics is -6.54. Candel Therapeutics’s PEG ratio is 0.08.
- PE Ratio
- -6.54
- PS Ratio
- 0.00
- PB Ratio
- 5.42
- Price to FCF
- -12.31
- Price to Operating Cash Flow
- -12.20
- PEG Ratio
- 0.08
Income Statement
In the last 12 months, Candel Therapeutics had revenue of 0 and earned -38.18M in profits. Earnings per share was -0.72.
- Revenue
- 0
- Gross Profit
- 0
- Operating Income
- -48.27M
- Pretax Income
- -38.18M
- Net Income
- -38.18M
- EBITDA
- -35.22M
- Earnings Per Share (EPS)
- -0.72
Cash Flow
In the last 12 months, operating cash flow was -56.02M and capital expenditures -1.30M, giving a free cash flow of -57.32M billion.
- Operating Cash Flow
- -56.02M
- Free Cash Flow
- -57.32M
- Free Cash Flow per Share
- -0.77
Dividends & Yields
Candel Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―
- Dividend Per Share
- ―
- Dividend Yield
- ―
- Payout Ratio
- N/A
- Free Cash Flow Yield
- -8.12%
- Earnings Yield
- -12.94%
Stock Price Statistics
- Beta
- 1.31
- 52-Week Price Change
- 83.67%
- 50-Day Moving Average
- 10.20
- 200-Day Moving Average
- 8.39
- Relative Strength Index (RSI)
- 51.21
- Average Volume (3m)
- 1.18M
Important Dates
Candel Therapeutics upcoming earnings date is Apr 01, 2027, TBA (Not Confirmed).
- Last Earnings Date
- Nov 05, 2026
- Next Earnings Date
- Apr 01, 2027
- Ex-Dividend Date
- ―
Financial Position
Candel Therapeutics as a current ratio of 13.31, with Debt / Equity ratio of 3.67%
- Current Ratio
- 13.31
- Quick Ratio
- 13.31
- Debt to Market Cap
- 0.01
- Net Debt to EBITDA
- 3.35
- Interest Coverage Ratio
- -22.78
Taxes
In the past 12 months, Candel Therapeutics has paid 0 in taxes.
- Income Tax
- 0
- Effective Tax Rate
- 0.00
Enterprise Valuation
Candel Therapeutics EV to EBITDA ratio is -6.67, with an EV/FCF ratio of -9.67.
- EV to Sales
- 0.00
- EV to EBITDA
- -6.67
- EV to Free Cash Flow
- -9.67
- EV to Operating Cash Flow
- -9.89
Balance Sheet
Candel Therapeutics has $201.56M in cash and marketable securities with $49.52M in debt, giving a net cash position of $152.05M billion.
- Cash & Marketable Securities
- $201.56M
- Total Debt
- $49.52M
- Net Cash
- $152.05M
- Net Cash Per Share
- $1.99
- Tangible Book Value Per Share
- $1.70
Margins
Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
- Gross Margin
- 0.00%
- Operating Margin
- 0.00%
- Pretax Margin
- 0.00%
- Net Profit Margin
- 0.00%
- EBITDA Margin
- 0.00%
- EBIT Margin
- 0.00%
Analyst Forecast
The average price target for Candel Therapeutics is $21.50, which is 11.43% higher than the current price. The consensus rating is Strong Buy
- Price Target
- $21.50
- Price Target Upside
- 133.19% Upside
- Analyst Consensus
- Strong Buy
- Analyst Count
- 6
- Revenue Growth Forecast
- ―
- EPS Growth Forecast
- -108.75%
Scores
- Smart Score
- 9
- AI Score
- 51
